The main objective of this study is to evaluate the efficacy and safety of 24 hours of closed-loop glucose control compared with standard diabetes treatment, in patients with type 2 diabetes treated by non-insulin glucose-lowering medications. This group is being studied as it is representative of patients with glucose dysregulation.
Algorithm driven closed-loop enables automated subcutaneous delivery of insulin in response to real-time continuous glucose sensor readings. Our studies to date have assessed the safety and efficacy of closed-loop insulin delivery in patients with type 1 diabetes in a controlled setting. For patients with type 2 diabetes treated by diet or non-insulin glucose-lowering medications alone, an episode of acute illness may result in elevated glucose levels necessitating initiation of insulin replacement therapy to optimise glycaemic control. Insulin may also be required in patients with no prior history of diabetes, presenting with 'stress hyperglycaemia'. Closed-loop systems may be of benefit in such insulin-naive patients in whom the optimal dosing regimen is difficult to establish, and may provide a safer method of insulin delivery with the added benefit of continuous monitoring of glucose levels on general hospital wards, thus minimising the likelihood of hyper- and hypoglycaemic events and their known associated worse outcomes. The study has an open-label, randomised, two-period crossover design. Participants will be randomised to undergo two 24-hour studies in a clinical research facility, during which glucose levels will be controlled by either the computer-based closed-loop algorithm (intervention) or by patients' usual non-insulin glucose-lowering diabetes treatment regimen (control). A continuous glucose sensor will be inserted on arrival for each visit. Participants will consume regular meals (matched on both visits) and carry out daily activities mimicking those occurring in an inpatient setting. Stable glucose isotopes will be administered on the two study occasions to collect data for modeling of glucose turnover around meals and during the overnight period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
Usual non-insulin glucose lowering medications
Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital
Cambridge, United Kingdom
Percent of plasma glucose values within target range 3.9-8.0 mmol/l
Time frame: 24 hrs
Percent of sensor glucose values within target range 3.9-8.0 mmol/l
Time frame: 24 hrs
Percent of plasma and sensor glucose values below 3.9 mmol/l
Time frame: 24 hrs
Percent of plasma and sensor glucose values above 8.0 mmol/l
Time frame: 24 hrs
Mean plasma and sensor glucose
Time frame: 24 hrs
Mean plasma insulin concentration
Time frame: 24 hrs
Total basal insulin insulin delivery
Time frame: 24 hrs
Low blood glucose index (LBGI) score
Time frame: 24 hrs
High blood glucose index (HBGI) score
Time frame: 24 hrs
Hyperglycaemic index score
Time frame: 24 hrs
Percent of plasma and sensor glucose values below 3.0 mmol/l
Time frame: 24 hrs
Standard deviation of plasma glucose
Time frame: 24 hrs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Frequency of hypoglycaemia
Time frame: 24 hrs
Frequency of hyperglycaemia
Time frame: 24 hrs